View all the latest information in myelodysplastic syndromes, arranged by therapeutic class and intervention. Listed below are recently updated therapeutic classes.
Progress in immunotherapy for hematologic malignancies
Immunotherapy has long been part of the armamentarium of therapies for hematologic malignancies. One of the first applications of immunotherapy...
DRSS: A new disease risk stratification system for hematologic malignancies
The success of allogeneic hematopoietic stem cell transplantation (allo-HSCT) is largely dependent upon disease type and...
NCCN COVID-19 vaccination recommendations for patients with hematologic malignancies
Patients with cancer are at high risk of COVID-19-associated complications and, accordingly, the preliminary...
Initiation of the first-in-human trial of allogeneic NKG2D-directed CAR NK-cell therapy to treat R/R AML or high-risk R/R MDS
Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) are...
Augmented reduced-intensity allo-HSCT in patients with high-risk AML or MDS: Results of the FIGARO trial
Previously, older patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS)...
Outcomes of patients with CMML treated with hypomethylating agents
Hypomethylating agents (HMAs) currently remain the only approved drugs for the management of chronic myelomonocytic leukemia (CMML),...
How can immunotherapy be used in MDS?
During the European School of Haematology (ESH) 2nd Translational Research Conference: Erythropoiesis Control and Ineffective Erythropoiesis - From Bench to...
JSP191 conditioning for patients with AML or MDS: Preliminary results from a phase I clinical trial
During the 2021 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, positive...
Cytokine receptor agonists
TGF-β pathway inhibitors